|
|
| | 3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate Basic information |
| Product Name: | 3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate | | Synonyms: | 3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate;Sofinicline benzenesulfonate | | CAS: | 876170-44-4 | | MF: | C16H17Cl2N3O3S | | MW: | 402.29 | | EINECS: | | | Product Categories: | | | Mol File: | 876170-44-4.mol | ![3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate Structure](CAS/20180808/GIF/876170-44-4.gif) |
| | 3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate Chemical Properties |
| | 3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate Usage And Synthesis |
| Uses | Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) is a novel nicotinic acetylcholine receptor agonist, specifically acting on the α4β2 subtype of nAChR (IC50=0.1 nM). Sofinicline benzenesulfonate has the potential to improve cognitive function, including attention, memory and working memory. Sofinicline benzenesulfonate can be used in studies of attention deficit, hyperactivity disorder (ADHD)[1]. | | References | [1] Fleisher C, et al. Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder[J]. Expert opinion on investigational drugs, 2014, 23(8): 1157-1163. DOI:10.1517/13543784.2014.934806 |
| | 3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate Preparation Products And Raw materials |
|